Neoplasma. 2017;64(6):916-921. doi: 10.4149/neo_2017_615.
Cutaneous angiosarcoma (CA) is extremely rare, and little is known about the biological significance of possible biomarkers for chemotherapeutic agents. Thymidylate synthase (TS) is an attractive target for cancer treatment in various human neoplasms. It remains unclear whether the expression of TS is associated with the clinicopathological features of CA patients. The aim of this study was to elucidate the relationship between TS expression and the clinicopathological significance in CA patients. Fifty-one patients with CA were included in this study. TS expression and Ki-67 labeling index were examined using immunohistochemical analysis. TS was positively expressed in 39% (20/51) of CA patients. No statistically significant prognostic factor was identified as a predictor of overall survival (OS) for all patients by univariate analysis, whereas a significant prognostic variable for progression free survival (PFS) was found to be the clinical stage. In addition, both univariate and multivariate analyses confirmed that positive expression of TS was a significant predictor of worse PFS in CA patients of clinical stage 1.
Positive TS expression in CA was identified as a significant predictor of worse outcome in patients of clinical stage 1.
阐明胸苷酸合成酶（TS）在血管肉瘤患者中的表达与临床病理特征的关系。
本研究纳入了 51 例血管肉瘤患者。采用免疫组织化学分析检测 TS 表达和 Ki-67 标记指数。
39%（20/51）的血管肉瘤患者 TS 呈阳性表达。单因素分析未发现任何统计学显著的预后因素可预测所有患者的总生存期（OS），而无进展生存期（PFS）的显著预后变量为临床分期。此外，单因素和多因素分析均证实，临床分期为 1 期的患者中，TS 阳性表达是 PFS 较差的显著预测因子。
血管肉瘤中 TS 的阳性表达被确定为临床分期为 1 期患者不良预后的显著预测因子。
